California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

Finally, the number of opportunities in the biosimilars space is very high — there are more than 300 biologics in the market, ...

PTC Therapeutics has received FDA approval for a gene therapy to treat AADC deficiency, a rare genetic disorder that impairs ...

The global contract development and manufacturing organization ​ (CDMO), Samsung Biologics, announced this week that it has ...

A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over ...

The STOX Suite is a digital platform that standardizes the measurement of steroid-toxicity, enabling researchers and ...

From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of ...

The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.

Alentis’ Series D financing round this week, marks the largest ADC-related fundraising in Europe in 2024. Other notable ...